These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10834859)

  • 1. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
    Van den Bosch F; Kruithof E; Baeten D; De Keyser F; Mielants H; Veys EM
    Ann Rheum Dis; 2000 Jun; 59(6):428-33. PubMed ID: 10834859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
    Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Mezières M; Alexandre C; Dougados M
    Rheumatology (Oxford); 2002 Nov; 41(11):1280-5. PubMed ID: 12422001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab in patients with primary Sjögren's syndrome: a pilot study.
    Steinfeld SD; Demols P; Salmon I; Kiss R; Appelboom T
    Arthritis Rheum; 2001 Oct; 44(10):2371-5. PubMed ID: 11665979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.
    Kruithof E; Van den Bosch F; Baeten D; Herssens A; De Keyser F; Mielants H; Veys EM
    Ann Rheum Dis; 2002 Mar; 61(3):207-12. PubMed ID: 11830424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcome of spondyloarthropathy with infliximab].
    Głowska A; Wiland P; Szechiński J
    Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
    Haroon M; Ahmad M; Baig MN; Mason O; Rice J; FitzGerald O
    Arthritis Res Ther; 2018 Apr; 20(1):73. PubMed ID: 29665824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
    Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
    Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
    Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF-alpha treatment--an effective complement in spondyloarthropathy].
    Mandl T; Jacobsson L
    Lakartidningen; 2002 Dec; 99(51-52):5189-93. PubMed ID: 12572316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of infliximab in resistant psoriatic arthritis.
    Salvarani C; Cantini F; Olivieri I; Macchioni P; Padula A; Niccoli L; Catanoso MG; Scocco GL; Boiardi L
    Arthritis Rheum; 2003 Aug; 49(4):541-5. PubMed ID: 12910561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.